COVID-19 represents an unprecedented health, social and economic challenge in Australia and around the world. Support Burnet’s COVID-19 emergency response today.
This involves identifying and prioritising candidate antigens for vaccine development, determining the optimal formulation and delivery of vaccine antigens, and developing assays to measure vaccine-induced immune responses that can be used in vaccine development and clinical trials.
Studies focus on several leading candidate antigens (AMA1, EBAs, PfRh, MSP2), and also aims to identify and characterise other antigens that could be developed as vaccines.
Work is also undertaken on vaccine approaches to induce potent protective immune responses.